1/10 This shouldn't even be a debate. Who could argue against this? Knowledge is the ultimate public good, & to restrict access to scientific papers to those at academic institutions w/subscriptions to journals is a crime.
2/10 Out-of-control, continually strengthening copyright & patent laws are an economic weapon wielded by the rich against the poor and by enormous, monopolistic firms against small firms. This is a major driver of inequality that receives scant attention. cepr.net/technology-pat…
3/10 The alleged justification for strong IP laws is that they incentivize & facilitate innovation. But as @DeanBaker13 points out in his indispensable (& free) book Rigged, in their current form, IP protections greatly impede innovation. See Ch. 5 deanbaker.net/books/rigged.h…
4/10 How much has medical progress been stifled by the patent-driven secrecy under which private research is cloaked? And by the gross distortions that drive companies to pursue expensive, patentable treatments & ignore cheap, often greatly superior treatments? (Rigged, Ch. 5)
5/10 Apart from the baleful economic & scientific effects of our IP laws, it's worth considering some more indirect effects these laws have on public health. Patent monopolies unquestionable cause corruption in the pharmaceutical industry. @DeanBaker13 on the opioid crisis:
6/10 Understandably, the rampant corruptions & recurrent scandals in the pharma industry have led to public distrust. Skepticism about Big Pharma claims is of course justified, but it has led some to reject anything connected to pharma, including vaccines. statnews.com/2019/02/26/ant…
7/10 The anti-vaccine movement's claims are of course absurd & tremendously harmful to public health, but their outright rejection of all scientific evidence largely stems from the never-ending flow of pharma-industry scandals, which are a predictable result of patent monopolies.
8/10 There's been much discussion of how to combat misinformation during the pandemic, but little talk of one of the root causes: patent-monopolies. Public financing of drug research could eliminate patent monopolies & allow drugs to be sold at generic, free-market prices.
9/10 Until we reform our rotten, corrupt, patent-monopoly-driven pharma industry, public skepticism of even impeccable medical research will remain, and such distrust will continue to be exploited by charlatans & mountebanks peddling noxious nonsense, w/grave public consequences.
10/10 Chart in tweet #8 is from chapter 5 of @DeanBaker13's book 'Rigged.' The book is freely available in digital form, & an awesome intro into some of the most pressing economic issues of our time. Definitely give Ch. 5 a read if nothing else. deanbaker.net/books/rigged.h…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Quick BA.3.2 update. Another BA.3.2.2 (S:K356T+S:A575S branch) from South Africa via pneumonia surveillance.
This means that 40% of SARS-CoV-2 sequences from SA collected since April 1 (2/5) and 50% collected after May 1 (1/2) are BA.3.2. Its foothold seems strong there. 1/3
2 interesting aspects of the new BA.3.2: 1. ORF1b:R1315C (NSP13_R392C)—This mut is in all Omicron *except* BA.3. So this may well be adaptive.
2. S:Q183H—First known antigenic spike mut seen in BA.3.2, not a major one, but one we've seen before—eg, LB.1/JN.1.9.2.1 2/3
I think the unusually long branches in the BA.3.2 tree indicate 2 things: 1. Slow growth globally—fast growth results in many identical sequences, if surveillance is sufficient
2. Undersampling—BA.3.2 most common in poorer world regions with little sequencing of late. 3/3
@yaem98684142 @TBM4_JP This analysis is extremely flawed.
There is nothing abnormal about BA.2.86 appearing in multiple countries shortly after discovery. This has been the norm lately w/reduced surveillance. 1/
@yaem98684142 @TBM4_JP The mutational spectrum analysis is poorly done. It cites a single study looking at the mutational spectrum in *three* immunocompromised individuals. Needless to say, this sample size is WAY too small. 3/
@yaem98684142 @TBM4_JP Furthermore, the IC people examined did not give rise to highly divergent variants with a large number of spike mutations. They appear to have accumulated a very modest number of mutations, with few substitutions in spike. The sequences themselves are apparently not published. 4/
Interesting recombinant showed up today from Texas. It's a mixture of B.1.595, BA.1, and some flavor of JN.1. Most of the genome is from B.1.595. The ancestry of this one is clear: it directly descends from a B.1.595 sequence collected in January 2023, also in Texas. 1/11
When the B.1.595 was collected this infection was >1 yr old, w/no sign of Omicron. BA.1 ceased circulating ~1 year prior.
Now a BA.1 spike appears w/just 5 changes from baseline BA.1, none in the RBD—S12F, T76I, Q271K, R765H, S939F.
This is a zombie BA.1 spike. 2/
There are only a few signs of JN.1, & they're scattered. In ORF1a, we see JN.1's V3593F, P3395H, & R3821K, but the NSP6 deletion btwn these—universal in Omicron—is absent. In
M has JN.1's D3H + T30A & E19Q (in JN.1 & BA.1), yet A63T—also in both BA.1 & JN.1 is absent. 3/11
An awesome preprint on the novel, unsung SARS-CoV-2 N* protein came out recently, authored by @corcoran_lab & Rory Mulloy. I’ve previously written on N*’s demise in XEC, the top variant in late 2024/early 2025. But…
1/34
…this preprint, along with another great study by the @DavidLVBauer, @theosanderson, @PeacockFlu & others prompted me to take a closer look...
2/34biorxiv.org/content/10.110…
...and for reasons I’ll describe below, I now believe rumors of N*’s death are exaggerated.
First, XEC is in terminal decline, replaced by variants with full N* expression, so N* is back in fashion.
3/34 journals.plos.org/plosbiology/ar…
@DameSunshine @SharonBurnabyBC B.1.1.529 wasn't/isn't a real variant; it's a placeholder that represents a putative ancestor of BA.1/BA.2/BA.3.
Bad sequences and/or coinfections tend to get categorized as B.1.1.529:—they have enough Omicron muts to be ID'd as Omicron but so much dropout/mixed signals...
1/
@DameSunshine @SharonBurnabyBC ...that a specific designation isn't possible. Travel sequencing in the US is done by Ginkgo Bioworks. Their sequences are generally poor quality & they upload *pooled* sequences—against database guidelines. The B.1.1.529 here are likely low-quality/pooled sequences from GBW.
2/
@DameSunshine @SharonBurnabyBC I think it's entirely possible that a new, divergent variant will emerge this summer. There are hints with BA.3.2 & a 50-spike-mutation BQ.1.1 that has transmitted at least once. Other similar chronic infection-derived variants are undoubtedly lurking all over, unsequenced.... 3/